Unique features of trabectedin mechanism of action Annette K. LarsenCarlos M. GalmariniMaurizio D’Incalci Review Article 14 December 2015 Pages: 663 - 671
Epigenetic alternations and cancer chemotherapy response Jin-Feng LvLei HuLan Fan Review Article 26 December 2015 Pages: 673 - 684
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens Gareth J. VealJulie ErringtonTanzina Chowdhury Original Article Open access 13 February 2016 Pages: 685 - 692
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study Steven J. CohenBert H. O’NeilLawrence Leichman Original Article 17 February 2016 Pages: 693 - 701
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy Yanli LiZandra KlippelJohn H. Page Original Article Open access 17 February 2016 Pages: 703 - 712
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer Dimitrios T. TrafalisConstantinos AlifierisNikolaos Sitaras Original Article 18 February 2016 Pages: 713 - 722
Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients Seong-Jang KimPhillip J. KooSamuel Chang Original Article 18 February 2016 Pages: 723 - 731
Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection Anubha GuptaZiad HusseinBruce A. Wallin Original Article 22 February 2016 Pages: 733 - 743
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors Varun GoelEunju HurhDalila Sellami Original Article 22 February 2016 Pages: 745 - 755
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A Ya-Tian ChenFeng ZhuLing-Hui Zeng Original Article 22 February 2016 Pages: 757 - 765
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies David PlanchardKathryn H. BrownPaul A. Dickinson Original Article 22 February 2016 Pages: 767 - 776
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity Charles GuenanciaOlivier HachetCatherine Vergely Original Article 25 February 2016 Pages: 777 - 785
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors Kenji TamuraJun HashimotoTaito Esaki Original Article Open access 01 March 2016 Pages: 787 - 795
Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo Bingfei XuYu WangHansong Du Original Article 01 March 2016 Pages: 797 - 806
Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma Daniele OuelletNastya KassirKiran Patel Original Article 03 March 2016 Pages: 807 - 817
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial) Russell PettyAlan AnthoneyRamón Salazar Original Article 10 March 2016 Pages: 819 - 827
Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients Srinivasu PoondruJorge ChavesStanley Gill Original Article 14 March 2016 Pages: 829 - 837
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers Beverly KnightDanielle RassamReginald Ewesuedo Original Article Open access 16 March 2016 Pages: 839 - 846
Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis Patrick BorentainSylvie CarmonaRené Gérolami Original Article 17 March 2016 Pages: 847 - 856
Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors Maurizio LucchesiMilena GuidiIacopo Sardi Original Article 17 March 2016 Pages: 857 - 864
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis Dong-Yeop ShinSeok Jin KimWon Seog Kim Clinical Trial Report 16 March 2016 Pages: 865 - 873
Oxytocin as a protective agent in cisplatin-induced ototoxicity Zekiye Eda Bekmez BilmezSedat AydinEbru Kösemihal Short Communication 11 February 2016 Pages: 875 - 879
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases Siqing FuKirk S. CulottaRazelle Kurzrock Erratum 19 March 2016 Pages: 881 - 881